Biogen Inc Corporate Call Summary

Edited Brief of BIIB.OQ conference call or presentation 14-Jan-21 2:00pm GMT

...ADI has worked with Co. for a number of years. 1. Interested in the fact that ADI's membership includes people that would be eventually beneficiary of what Co. is doing. a. 2. Back in Nov., Co. presented aducanumab for approval to the Food and Drug Administration in US. Committee didn't seem to analyze in great detail what aducanumab did. a. b. Concerned, due to COVID-19, FDA may be distracted and may not consider how important is the presentation of effectively what's the first possible medication in ADI's area that could come into the market in decades. 3. ADI waits with patients' optimism for final FDA findings, which should happen in the next few months. For ADI, priority must be ensuring that healthcare systems are prepared, especially tackling the difficult areas of diagnosis. a. Diagnosis is crucial in order to be able to use this medication and crucial for ADI to have transparency around access and cost. i. b. Wants government to be in a position that they adopt this. 4. Will continue...

Brief